Aralez Pharma (ARLZ) Misses Q1 EPS by 48c

Aralez Pharma (NASDAQ: ARLZ) reported Q1 EPS of ($0.73), $0.48 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.06 million versus the consensus estimate of $9.7 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c